Perrigo Company plc
PRGOPerrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
PRGO Earnings Report
EPS Est: $0.31 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
How PRGO's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
pseudoephedrine hydrochloride 30 mg tablets | Phase 3 | Nasal Congestion Associated With the Common Cold | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Perrigo Company plc's drug pipeline?→
CatalystAlert tracks 1 drug candidate in Perrigo Company plc's (PRGO) pipeline across Phase 3. Its lead program is pseudoephedrine hydrochloride 30 mg tablets (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Perrigo Company plc's next FDA catalyst?→
Perrigo Company plc's (PRGO) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PRGO biotech catalysts?→
Add PRGO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Perrigo Company plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.